Urothelial carcinoma: Stem cells on the edge |
| |
Authors: | William D. Brandt William Matsui Jonathan E. Rosenberg Xiaobing He Shizhang Ling Edward M. Schaeffer David M. Berman |
| |
Affiliation: | 1. Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, 21231, USA 2. Department of Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD, 21231, USA 4. Lank Center for Genitourinary Cancer, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, 02115, USA 3. Department of Urology, The Johns Hopkins Medical Institutions, Baltimore, MD, 21231, USA
|
| |
Abstract: | Tumors are heterogeneous collections of cells with highly variable abilities to survive, grow, and metastasize. This variability likely stems from epigenetic and genetic influences, either stochastic or hardwired by cell type-specific lineage programs. That differentiation underlies tumor cell heterogeneity was elegantly demonstrated in hematopoietic tumors, in which rare primitive cells (cancer stem cells (CSCs)) resembling normal hematopoietic stem cells are ultimately responsible for tumor growth and viability. Because of the compelling clinical implications CSCs pose—across the entire spectrum of cancers—investigators applied the CSC model to cancers arising in tissues with crudely understood differentiation programs. Instead of relying on differentiation, these studies used empirically selected markers and statistical arguments to identify CSCs. The empirical approach has stimulated important questions about “stemness” in cancer cells as well as the validity and stoichiometry of CSC assays. The recent identification of urothelial differentiation programs in urothelial carcinomas (UroCas) supports the idea that solid epithelial cancers (carcinomas) develop and differentiate analogously to normal epithelia and provides new insights about the spatial localization and molecular makeup of carcinoma CSCs. Importantly, CSCs from invasive UroCas (UroCSCs) appear well situated to exchange important signals with adjacent stroma, to escape immune surveillance, and to survive cytotoxic therapy. These signals have potential roles in treatment resistance and many participate in druggable cellular pathways. In this review, we discuss the implications of these findings in understanding CSCs and in better understanding how UroCas form, progress, and should be treated. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|